Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Johnson & Johnson

Pfizer

These strengthening tailwinds will power future returns.

4 Reasons to (Still) Be Optimistic About Coronavirus Vaccine Stocks

Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.

Moderna ETFs to Shine Bright on Booster Update, New Study Data

Moderna Inc. (NASDAQ:MRNA) shares on Friday edged slightly higher after news the company's covid-19 vaccine received a green light from the FDA for use as a booster shot. The FDA also greenlighted Pfizer Inc. (NYSE:PFE) and BionTech's covid-19 vaccine for booster shot use.

The FDA allows Moderna Covid vaccine for use as booster shot: should you buy now?

Year-to-date, shares of BioNTech, Moderna, and Pfizer have surged 357%, 275%, and 28%, respectively.

Moderna and Pfizer rebound after FDA authorizes third COVID-19 booster shot for immunocompromised

Pfizer and Moderna could make billions of dollars from COVID-19 booster shots, earnings comparable to the $6 billion generated each year in flu vaccine sales. That's according to a Friday (Aug. 13) report from Reuters, which says the companies expect vaccinated people will need boosters to project against the coronavirus and new variants.

Pfizer, Moderna Could Make Billions From COVID Boosters

BioNTech SE

The FDA authorized booster doses for immunocompromised individuals.

Why Pfizer, BioNTech, and Moderna Stocks Are Getting a Bump Today

Shares of Moderna Inc. MRNA, +1.58% ran up 3.4% in premarket trading Friday, after the Food and Drug Administration authorized a third shot of COVID-19 vaccines from Moderna and Pfizer-BioNTech for immunocompromised adults. The booster shot will be for people who have undergone organ transplants, who are undergoing chemotherapy and those taking chronic medications that can suppress immune systems.

Moderna stock rallies after FDA OKs booster shot of COVID-19 vaccine for most at-risk adults

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces FDA authorization of third dose of COVID-19 vaccine for immunocompromised individuals.

Moderna Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals

Chewy

EOG Resources

Pinterest

Roku

Schlumberger

We have narrowed down our search to six large-cap stocks that have attained a 52-week high this year but are currently trading at a sharp discount. These are: CHWY, PINS, ROKU, SLB, EOG and MRNA.

6 Stocks to Buy on the Dip With Strong Upside Left for 2021

The biotech's coronavirus tailwind is far from over.

Moderna Says Booster Shots Are Coming. What Does It Mean for the Stock?

Moderna Inc (NASDAQ: MRNA) announced the publication of a new study showing that its COVID-19 vaccine led to durable antibody levels against variants of concern. According to the report published in the journal Science, most individuals retained binding and neutralizing antibodies against variants for six months following the second dose.

Moderna's COVID-19 Vaccine Retains Antibodies Against Variants For 6 Months

We're seeing the laws of supply and demand at work.

Why Are Pfizer and Moderna Jacking Up COVID Vaccine Prices?

Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.

Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster market

Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.

Moderna study shows its COVID-19 vaccine holds up against several variants after six months

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new study showing its COVID-19 vaccine maintains antibodies against variants of concern and interest to 6 months.

Moderna Announces New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants of Concern and Interest to 6 Months

Moderna Inc (NASDAQ: MRNA) shares have tanked more than 20% from record levels noted on Monday after reporting market-beating quarterly results last week. Much of the decline was driven from BofA's Geoff Meacham, who said in a note yesterday that the biotech firm should be about 75% below its current price.

Analyst: “no other company will have an mRNA booster like Moderna”

The shares of Moderna Inc (NASDAQ: MRNA) increased by over 5% during intraday trading. This is why it happened.

Moderna Shares Increase Over 5% Intraday: Why It Happened

Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.

mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally

Microsoft

Netflix

NIKE

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Netflix among others.

AI Identifies Netflix Among Today's Trending Stocks

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Do Options Traders Know Something About Moderna (MRNA) Stock We Don't?

Wall Street analysts appear less keen than retail traders on vaccine makers such as Moderna, after a breakneck rally over the last year.

Moderna was the most-bought stock for retail traders in the week leading up to its 16% single-day plunge

As one of the leaders of messenger RNA (mRNA) vaccine technology, there is certainly a lot to like about Moderna's future.

Moderna: The Rally Is Over For Now

The pre-print study suggested the Pfizer vaccine was 34 points less effective in preventing infection last month, at least in one state, NBC New York reports.

Mayo Clinic: COVID Breakthrough Risk May Be Much Lower With Moderna Than Pfizer

The study charted the effectiveness of mRNA vaccines given out in the Mayo Clinic Health System in Minnesota between January and July.

Pfizer's vaccine efficacy dropped to 42% while Moderna's was at 76% when the Delta variant became the dominant strain, study says

Editas Medicine

Editas could be an attractive acquisition candidate for the big vaccine maker.

News for Moderna Stock (MRNA)